EnfuvirtideImmuneSafety Rating 8/10
Primary research areaHIV-1 infection in treatment-experienced patients
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Research dose range90 mg twice daily SC
AdministrationSubcutaneous injection
Safety8/10 · FDA-approved (Fuzeon)
NCAA D1Permitted
Price Comparison
Compare vendors
No vendor pricing available for this peptide yet.
Overview
About Enfuvirtide
Mechanism of action
Fusion inhibitor T-20 peptide; prevents HIV envelope gp41 hairpin formation and cell membrane fusion
Safety profile
Injection site reactions nearly universal, bacterial pneumonia; rarely used today · Approved for HIV; injection site reactions in 98% (local, not systemic); hypersensitivity rare
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops Enfuvirtide below your target.
Related pages